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Abstract
Background: Mutations and promoters’ methylation of a set of candidate cancer genes (CAN genes) are associated with
progression of colorectal cancer (CRC). We hypothesized that these genes’ promoters are inactivated through epigenetic
silencing and may show a different profile in high-risk populations. We investigated the status of CAN gene methylation and
CHD5 protein expression in African American CRC tissue microarrays (TMA) using immunohistochemical staining.
Methodology/Principal Findings: The promoter methylation status of the CAN genes was studied by methylation-specific
PCR (MSP) in 51 Iranians (a white population) and 51 African Americans (AA). Microsatellite instability (MSI) was analyzed as
well. The differential frequency of methylation for each gene was tested by chi-square analysis between the two groups
based on matched age and sex. CHD5 protein expression was evaluated in moderate to well differentiated and poorly
differentiated carcinomas compared to matched normal tissue using TMA. In addition, the correlation between these
epigenetic biomarkers and various clinicopathological factors, including, age, location, and stage of the disease were
analyzed. Seventy-seven and 34% of tumors were distal in Iranian and African American patients, respectively. In both
populations, the percentage of methylation was .65% for SYNE1, MMP2, APC2, GPNMB, EVL, PTPRD, and STARD8, whereas
methylation was ,50% for LGR6, RET, CD109, and RNF. The difference in methylation between the two populations was
statistically significant for CHD5, ICAM5 and GPNMB. Thirty-one percent AA tumors showed MSI-H, compared to 28% in
Iranians.
Conclusions/Significance: A significantly higher methylation rate was found for GPNMB, ICAM5, and CHD5 genes in AA
patients compared to Iranians. These genes might play a role in the high incidence and aggressiveness of CRC in the AA
population. The hypermethylation of the CAN genes can be considered as a marker of colon carcinogenesis.
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Introduction
Colon cancer (CRC) remains the most prevalent gastrointestinal
cancer in the United States [1]. The incidence and mortality rate
of CRC are higher in AA [2,3]. A significant increase in CRC
incidence with a predominant distal localization has also been
reported in Iran over the last decade [4,5].
One of the CRC pathways involves transcriptional silencing by
hypermethylation of CpG islands, which is referred to as the
methylator phenotype (CIMP
+) [6] that mostly targets promoter
regions of tumor suppressor genes (e.g., p16 and hMLH1 genes)
[7,8,9]. It has recently been shown that genetic and epigenetic
alterations of some candidate cancer genes (CAN genes) including;
SYNE1, MMP2, GPNMB, APC2, EVL, PTPRD, CDH5, LGR6,
STARD8, CD109, ICAM5, CHD5, RNF, and RET, are
important in the progression of CRC [10,11].
The functional characterization of these genes with regards to
tumor progression has not been clarified completely. These genes
could be divided into 5 classes: (1) tumor suppressors, including
adenomatous polyposis coli tumor suppressor homolog 2 (APC2)
and protein-tyrosine phosphatase receptor type-delta (PTPRD); (2)
genes that encode receptors, including rearranged during
transfection proto-oncogene (RET), leucine-rich repeat-containing
G protein coupled receptor 6 (LGR6) and Ena/VASP like protein
(EVL); (3) genes known to be involved in protein–protein and
protein–DNA interactions, including STAR-related lipid transfer
(START) domain–containing 8 (STARD8), ring finger protein
(RNF182), CD109 antigen (CD109), glycoprotein NMB
(GPNMB); (4) genes involved in metastasis and tumor growth,
including intercellular adhesion molecule 5 (ICAM5), matrix
metalloproteinase 2 (MMP2), and synaptic nuclear envelope
protein 1 (SYNE1); and (5) genes whose expression is associated
with changes in chromatin structure, such as chromodomain
helicase DNA-binding protein 5 (CHD5).
These genes were chosen from many lists of potential cancer
genes [11,12] because recent studies showed that in non-AA CRC,
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fact, based on the comprehensive analysis by Sjoblom et al, where
systematic sequencing of CRC tumors revealed the importance of
these markers in CRC progression [11].
While most of these genes are novel, there is some functional
data available in the literature. The receptors for glycoprotein
hormones such as LGR6 are G protein–coupled 7-transmembrane
receptors [13]. SYNE1 contains multiple spectrin repeats and a
60-amino acid C-terminal region homologous to the Drosophila
protein Klarsicht. There are two mRNA isoforms, SYNE1A and
SYNE1B, in skeletal and cardiac muscle [14,15].
The metastatic potential of tumor cells has been found to
correlate with the activity of MMP2 enzyme [16] that are
functionally active on the surface of angiogenic blood vessels[16].
CD109 is a GPI-linked cell surface antigen expressed by CD34+
acute myeloid leukemia cell lines, T-cell lines, activated T
lymphoblasts, endothelial cells, and activated platelets [17]. The
RING finger motif is a specialized zinc finger domain including
RNF182 and is found in many transcriptional regulatory proteins
[18]. Mutations in the RET gene are associated with multiple
endocrine neoplasia, type IIA and IIB [19].
Alteration of CHD5 expression is associated with changes in
chromatin structure, through histones modification by acetylation
and methylation [20]. It was noted that soluble ICAM5 level
increased in the colony-stimulating factor of patients with acute
encephalitis [21]. GPNMB is preferentially expressed in low-
metastatic melanoma cell lines as glycoprotein [22]. In melanoma
metastasis, there is an inverse relationship between the expression
of GPNMB and calcyclin or thymosin-beta-10, two other potential
markers for the progression of cutaneous melanoma. Two-thirds of
highly metastatic melanomas expressing recombinant GPNMB
showed slower subcutaneous tumor growth, whereas one-third
showed reduced potential for spontaneous metastasis in nude mice
[22] or iris pigment dispersion in DBA/2J mice [23]. APC2 is
involved in a series of molecular signals initiated by the binding of
Wnt protein to a frizzled family receptor on the surface of the
target cell and ending with a change in cell state [24,25]. APC2
protein interacts with a microtubule-associated protein, which
effects beta-catenin-mediated growth signaling [24,25]. The co-
expression of the EVL protein along with alpha-II spectrin
reinforces cell–to-cell interaction. The methylation of the EVL
gene in all poorly differentiated tumors suggests that it is a factor in
cell invasiveness [26]. STARD8 was identified as a tumor
suppressor gene that inhibits cancer growth [27]. It is located on
chromosome Xq13 and encodes DLC-3 (related to Rho GTPase).
Transfection of human breast and prostate cancer cells with a
DLC-3alpha expression vector inhibited cell proliferation, colony
formation, and growth in soft agar [27].
In the present study, we analyzed samples from AA and Iranian
patients for methylation of CAN genes’ promoters. We hypoth-
esized that CAN genes were inactivated through epigenetic
silencing and may show distinct methylation profiles in different
populations.
Materials and Methods
Ethics Statement
This study was approved by Howard University Institutional
Review Board, and written informed consent was obtained.
Study population, and tumor samples
A total of 102 CRC samples were used. Fifty-one sporadic CRC
samples from Iranian patients, recruited at the hospitals of Shiraz
University of Medical Sciences from 2003 to 2005 and 51 CRC
samples from AA patients, recruited at Howard University
Hospital, matched by sex, age (with 65 years) and stage, were
included in this study. All samples were evaluated and subjected to
histological diagnosis by expert pathologists. Tissues were collected
(with approval from all above sites’ Institutional Review Boards
and clinical data was obtained (including race, age, site of primary
tumor, stage, and tumor differentiation). Family history of cancer
was analyzed to exclude those pedigrees that met either the
Amsterdam I or Amsterdam II criteria.
Methylation-specific PCR
The promoter methylation status of the CAN genes was
determined as described previously [28,29,30]. The sequences of
primers used for amplification of the promoter regions of each of
the CAN genes are listed in Table 1. The MS-PCRs were
performed as previously described (Table 1) [10]. The MSP
primers were designed using a software developed at the Johns
Hopkins University (www.mspprimers.org) [10] based on the
sequences for which the accession numbers and corresponding
function are given in Table 2. The PCR conditions were as follow:
hotstart Taq polymerase (Qiagen) used with initial activation and
denaturation 95uC615 min; 35 cycles [95uCx45 sec; 60uC645 -
sec; 72uC61 min] followed by final extension 72uC610 min. In
vitro methylated DNA and unmethylated lymphocytes DNA were
used as positive and negative controls, respectively. The annealing
temperature was 56uC for APC2 and CD109 [10], respectively,
while it was 60uC for all other genes (Table 1).
DNA isolation and MSI analysis
Archived and fresh tumor blocks were cut into 5-mm sections on
Superfrost slides (Fisher Scientific, Pittsburgh, PA). The tumor and
normal areas were diagnosed by a pathologist using the H&E
matched slide and microdissected to pinpoint the tumor and
normal areas from at least two slides. DNA extraction and MSI
(five microsatellite markers [31] (BAT25, BAT26, D17S250,
D5S346, and D2S123) were done according to our previous
studies [28,29,30]. Tumors with instability at only one of the
markers were labeled MSI-L, those with instability in two or more
markers were labeled MSI-H, and those with no instability were
labeled MSS. Due to unclear characteristics of MSI-L, we
combined MSS and MSI-L into one group (non-MSI-H).
Tissue Microarrays and Immunohiostochemical Analysis
Tissue microarrays (TMAs) were constructed using a Beecher
Instruments MTA-1 tissue arrayer. Each TMA contained tissue
from normal and tumor areas, based on a published protocol [32].
Duplicate tumor samples were taken from each tissue block. In
total, 116 cases were analyzed for CHD5 expression; moderate to
well differentiated (55 cases), and poorly differentiated (4 cases)
carcinomas with matched adjacent normal tissues (57 cases) were
available for control comparisons. A retrospective analysis for
outcome assessment was based on detailed clinicopathological
information linked to the TMA specimens. TMA obtained from
paraffin-embedded blocks was used for the immunohistochemistry
experiments. Sections (5 mm) were mounted on charged glass
slides, deparaffinized with xylene for 2610 min and rehydrated
using a graded ethanol series. Antigen retrieval was performed by
placing the samples in a microwave oven for 12 min, with
occasional interruption to avoid tissue degradation by excessive
heat. The slides were then treated with hydrogen peroxide,
followed by incubation with the primary and secondary antibod-
ies, a streptavidin-biotin complex, an amplification reagent,
streptavidin-peroxidase and substrate-chromogen solution using
the Envision system according to the manufacturers’ protocol
Colon Cancer, Gene Methylation
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ylin, rinsed with ethanol, dried and visualized by light microscopy.
Tissue samples to which no primary antibody had been added
were used as negative controls. All immunohistochemistry reagents
were purchased from DAKO (Carpinteria, CA). The CHD5
antibody (CHD5 clone H-185, 1/10 dilution) was purchased from
Santa Cruze (San Diego, CA). The slides were read by two
pathologists (E.L; R.G.) and the percentage of the cytoplasmic
staining was recorded.
Histopathological analysis
Independent pathologists evaluated specific histopathological
characteristics. Grading of tumors was achieved by staining with
Hematoxylin-Eosin (H&E). Tumors were classified as proximal or
distal (to the splenic flexure). The TNM system of the
International Union against cancer was used for tumor staging.
Statistical analysis
Age of patients was a continuous variable, while race, gender,
location, differentiation, stage, MSI, and CAN genes methylation
were categorical variables. The distribution of categorical variables
were shown by frequency table, and for age by computing mean
(SD). Associations between methylation of loci with age, race,
gender, differentiation, MSI, stage and tumor location were
evaluated using a chi square test. The age difference between two
groups was tested by the Student’s t test. All analysis were
performed using SPSS 15.0 software (Chicago, IL).
Results
Clinicopathological characteristics of patients
We analyzed 102 samples (38 females and 64 males) from Iranian
and AA patients (Table 3). The mean age (SD) for carcinoma in AA
was 61.5 (12) years and 60 (13) years in Iranians. There was no
significant difference in sex or age between the two analyzed
populations. A total of 57% and 24% of tumors were proximal in
the AA and Iranian patients, respectively. A higher incidence of
distal tumors was present in Iranians in comparison to the AA
(Table 3).Most tumors were at advanced stages with 57% at stage II
in Iranians, and 52% at stage III+IV in AA (Table 3). The majority
of tumors (85%) were found to be moderately differentiated in AA
while Iranian tumors were mostly well differentiated (53%).
SYNE1 and RNF182 gene methylation profiles
The SYNE1 promoter was found to be methylated in all 102
analyzed samples (Table 4). In addition, its methylation does not
seem to be specifically associated with any of the clinicopathological
parameters considered in this study and point to its importance in
colon tumorigenesis as a tumor suppressor gene. In contrast, the
Table 1. Primers used in this study.
Gene Sense sequence Antisense sequence
Product
size (bp)
Annealing
Temperature (uC)
No.
Cycles
APC2Unmeth 59- tGGtAGtGttGttTGtttAGGtttGGAttG -39 59- ACCaaAAATCCCaaCCCaaaaTaaCCTCaaAaCa -39
APC2Meth 59- GtCGttTGtttAGGttCGGAtC -39 59- GaCCCGaaaTaaCCTCGaAaCG -39 98 56 35
CD109Unmeth 59- GtAGtGGAtTGTAGtttAGGtAGAtGttGTtG -39 59- CaCaaCaaTaCACACaCAaAaaAaaTaaaCaaCa -39
CD109Meth 59- GAtTGTAGtttAGGtAGACGtCGTC -39 59- CGaTaCACACGCAaAaaAaaTaaaCGaCG -39 79 60 35
CHD5Unmeth 59- GGGAGGAGtGtttGGGtTTTGtG -39 59- CaaCaaaCaAaaCaaCCTCaaCaAaAAaATaaCa -39
CHD5Meth 59- GAGCGttCGGGtTTTGC -39 59- CGaCCTCGaCGAaAAaATaaCG -39 119 60 35
EVLUnmeth 59- GtGtGttTtTtttTtGAGGAtTtGGAGttGtttG -39 59- aCCaCCaaaaaATaaaaaaaCaaaaaaCaAaCCa -39
EVLMeth 59- GAGGAtTCGGAGtCGttC -39 59- CCGAaaaATaaaaaaaCGaaaaaCGAaCCG -39 119 60 35
GPNMBUnmeth 59- AGGttTGAGAtGTGGGttGtGttttG -39 59- CCAAAAACaTAaaCaTTTTCCCaaaTCaCAaTCa-39
GPNMBMeth 59- ACGTGGGtCGCGtttC -39 59- TAaaCGTTTTCCCGAaTCGCAaTCG -39 88 60 35
ICAM5Unmeth 59- tttAGttTTGtGTtttGGtTttGTGTTtTTtAttG -39 59- TCCTaaCAaAATaCCaaaATACaAaaAaAaTaCa -39
ICAM5Meth 59- CGTttCGGtTtCGTGTTtTTtAtC -39 59- CTaaCAaAATaCCGAaATACGAaaAaAaTaCG -39 116 60 35
LGR6Unmeth 59- tGGGtAGGGGtAtGGttAGGtG -39 59- CCCTAaCTaCACaCACaTACCCaaaAaCTAAaCa -39
LGR6Meth 59- GtAGGGGtACGGttAGGC -39 59- GCACGTACCCGAaAaCTAAaCG -39 94 60 35
MMP2Unmeth 59- GtGGttAtAtGtAttGAGttAGtGAtttttGGGtG -39 59- AaaAaACAaAaCaCCCTCAaaaaACCCaTaAaCa -39
MMP2Meth 59- tAtCGAGttAGCGAttttCGGGC -39 59- CGCCCTCAaaaaACCCGTaAaCG -39 96 60 35
RETUnmeth 59- ttGGttttGttTGGtttAttttTGGAttGtttttG -39 59- CTaCaCaCCCTaCTTCaaTCaCaaaACTaAAaCa-39
RETMeth 59- GGtttCGttTGGtttAttttTGGAtCGttttC -39 59- CTaCTTCGaTCGCGAaACTaAAaCG -39 104 60 35
RNF182Unmeth 59- GGtGGtTtAGtGttGTAGAGAtAAAGttGtttG -39 59- AaaaCCCaaaAaCCaCTCCaaCTaCaaCa -39
RNF182Meth 59- tTtAGCGtCGTAGAGAtAAAGtCGttC -39 59- GCTCCGaCTaCGaCG -39 109 60 35
STARD8Unmeth 59- tAGGGAttGGGtTGGtTtTtGttGAGttttG -39 59- aTaaaaAaCTTCTAaaaCCaaCaaaaCTaTaCCa -39
STARD8Meth 59- GGGtTGGtTtTCGtCGAGtttC -39 59- TTCTAaaaCCGaCGaaaCTaTaCCG -39 90 60 35
SYNE1Unmeth 59- GtGGtTGGGtTtttGtAGTttTGtAGAttGtG -39 59- CaaCTCTCTaCaCCCAaaCTCaaCa -39
SYNE1Meth 59- GtTGGGtTttCGtAGTttTGtAGAtCGC -39 59- CTaCGCCCAaaCTCGaCG -39 87 60 35
PTPRDUnmeth 59- tGGtGGGGTttGtttAGGttGtG -39 59- ATaCTCCaAaCaCCCaCTaaaaAaAaAAaCaaCa -39
PTPRDMeth 59- GGGGTtCGtttAGGtCGC -39 59- CGCCCGCTaaaaAaAaAAaCGaCG -39 120 60 35
doi:10.1371/journal.pone.0007012.t001
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(Table 4). This finding will put in question its status as a candidate
for methylation in colon cancer carcinogenesis.
Gender and CAN gene methylation
Nine out of 13 genes showed gender-independent levels of
methylation (Table 5). The RET gene displayed a higher level of
methylation in males (45%) than in females (29%). This difference,
however, was not found to be statistically significant. The APC2,
PTPRD and STRAD8 genes were found to have significantly
different methylation profiles in the two genders, with APC2 being
hypermethylated in males (98% vs. 90%); PTPRD and STARD8
were hypermethylated in females (90% vs. 67%) and (84% vs.
61%), respectively.
Age and CAN gene methylation
None of the 13 genes analyzed showed any age-dependent
methylation profile, although ICAM5 and CD109 showed non-
Table 2. CAN genes, their functions andcorresponding Accession number.
Gene Gene Name Gene Function References
Accession
Number
APC2 Adenomatosis polyposis coli 2 Wnt transduction pathway [25,26] NM_005883.2
CD109 CD109 molecule Expressed in CD34+ acute myeloid leukemia and other blood cell lines [17] NM_133493.2
CHD5 Chromodomain helicase DNA binding protein 5 Intervenes in chromatin modification through histones acetylation
and methylation
[21] NM_015557.1
EVL Enah/Vasp-like Strenghtens cell-to-cell interaction [27] NM_016337.2
GPNMB Glycoprotein (transmembrane) nmb Expressed in low metastatic melanomas cell lines [23] NM_001005340.1
ICAM5 Intercellular adhesion molecule 5, telencephalin Highly expressed in the colony-stimulating factor of patients with
acute encephalitis
[22] NM_003259.2
LGR6 Leucin-rich repeat-containing G protein-coupled
receptor 6
Receptor for glycoproteins Hormones [13] NM_021636.2
MMP2 Matric metallopeptidase 2 Active on angiogenic blood vessels, metastasis [16] NM_004530.2
PTPRD Protein tyrosin phosphatase, receptor-type, D TSG, involved in a wide range of common human cancers [51] NM_130391.2
RET Ret proto-oncogene Associated with multiple endocirine neoplasias type IIA and IIB [19] NM_020975.4
RNF182 Ring finger protein 182 Found to many transcriptional regulatory proteins [18] NM_152737.2
STARD8 START domain contain 8 TSG, inhibits cancer growth [27,52] NM_014725.2
SYNE1 Spectrin repeat containing, nuclear envelope 1 Expressed in skeletal and cardiac muscles [14,15] NM_182961.1
doi:10.1371/journal.pone.0007012.t002
Table 3. Clinical and demographical characteristics of CRC in
the two populations.
African Americans Iranians P
Number of patients 51 51
Mean (SD) age 61.5 (12) 60 (13) 0.5
Gender N (%) N (%)
Female 19 (37) 19 (37)
Male 32 (63) 32 (63) 1.0
Site
Distal 22 (43) 39 (77)
Proximal 29 (57) 12 (24) 0.001
Age
,60 24 (47) 29 (57)
$60 27 (53) 22 (43) 0.002
Differentiation
Poor 2 (4) 2 (4)
Moderate 39 (85) 22 (43)
Well 5 (11) 27 (53) 0.0001
Stage
0,1 9 (21) 8 (15)
2 12 (27) 29 (57)
3,4 23 (52) 14 (28) 0.01
MSI
High 10 (20) 14 (28)
Non- High 40 (80) 37 (72) 0.2
doi:10.1371/journal.pone.0007012.t003
Table 4. Methylation (%) comparison between two
populations.
Gene Iranians AA P-value
APC2 48 (94) 49 (96) 0.6
SYNE1 51 (100) 51 (100) 1
GPNMB 45 (89) 50 (100) 0.03
EVL 41 (79) 35 (71) 0.4
MMP2 51 (100) 48 (94) 0.2
CD109 16 (32) 15 (30) 0.8
CHD5 25 (47) 38 (78) 0.002
RNF182 0 0 1
LGR6 16 (31) 25 (49) 0.8
PTPRD 38 (76) 38 (76) 1
STARD8 33 (65) 38 (75) 0.3
RET 19 (37) 21 (41) 0.7
ICAM5 4 (7.5) 20 (40) 0.0001
doi:10.1371/journal.pone.0007012.t004
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consistent with the way the genes were chosen and supports the
idea that most of them are targeted by methylation in a
carcinogenic process.
Tumor location and CAN gene methylation
Ten of the analyzed genes have similar methylation levels,
regardless of the tumor location (Table 5). However, CD109,
LGR6, and ICAM5 displayed higher methylation levels in
proximal tumors than in distal ones. Methylation frequency of
CD109 was 43% in proximal tumors vs. 21% in distal tumors.
These numbers for ICAM5 were 34% in proximal and 16% in
distal tumors, respectively (p,0.05). For the LGR6 gene, the
difference (51% vs. 33%) was not statistically significant.
Tumor differentiation and CAN gene methylation
While 8 genes displayed different methylation profiles at
different levels of differentiation, only two showed statistically
significant differences (ICAM5 and MMP2). However, there was
no correspondence with tumor progression toward poor differen-
tiation (Table 5). Only the APC2 and EVL genes displayed higher
methylation in the normal progression of a tumor from well to
moderate to poor differentiation, with the APC2 gene showing
91%, 97%, and 100% and the EVL gene showing 75%, 77%, and
100%, respectively. These findings might underscore the role of
these genes in the tumor differentiation process.
Tumor stage and CAN gene methylation profile
Eight genes showed different methylation profiles at different
tumor stages, with the LGR6 and APC2 genes displaying
statistically significant differences with higher methylation at stage
1 and lower methylation at advanced stages in the case of LGR6
and lower methylation at stage 1 and higher methylation at
advanced stages in the case of APC2 (Table 5). The only gene that
showed a higher methylation at more advanced tumor stages was
CD109, which was methylated at a rate of 56%, 76%, and 86% at
stages I, II and (III+IV), respectively.
MSI and CAN gene methylation
The MSI rate was 28% for Iranians and 31% for AA (Table 3),
respectively. Twelve of the 13 tested genes showed no differences
in methylation levels between MSI-H and non MSI-H tumors in
both populations. An exception could be made for the PTPRD
gene with a statistically significant association with MSI-H
(P,0.05) in both populations (Table 5). Therefore, there is a
possibility that the methylation of PTPRD is linked to the MSI-H
phenotype.
Population to Population comparison
The methylation profiles of at least 9 genes in the two analyzed
populations was similar without significant differences (Table 4
and figure 1): APC2, SYNE1, EVL, MMP2, CD109, RNF182,
PTPRD, STARD, and RET. For the LGR6 gene, there was a
substantial difference, although statistically insignificant, in
methylation levels with 31% vs. 49% in Iranians and AA,
respectively. For three genes, namely GPNMB, CHD5, and
ICAM5, there were statistically significant differences in the
methylation level, with AA displaying higher methylation levels
than Iranians, 100%, 78%, and 40% vs. 89%, 47%, and 7.5% for
the three genes, respectively (Table 4)
CHD5 expression by IHC, Differentiation and Tumor
Stage
Since one of our laboratory’s main focuses is to tackle the issue
of the high incidence of CRC in AA and, based on the fact that
CHD5 promoter is highly methylated in this population and seems
to be involved in early stages of carcinogenesis as a chromatin
modifier, we analyzed its expression by IHC to validate the
methylation results. Among 59 CRC cases available for analysis,
the number of subjects with stage I, II, III, and IV were 14
(24.5%), 20 (35.1%), 21 (36.8), 2 (3.5%), and 2 (missing)
respectively. In general, there were no statistically significant
differences for age, sex, anatomic location, CHD5 expression with
tumor stage (data not shown). Expression of CHD5 (Fig. 2C) was
lost in 80% of AA patients and 52% in Iranian patients with stage
Table 5. Distribution of the CAN genes methylation (%) by demographic and clinical characteristics of CRC in the AA and Iranian
populations.
N=102 APC2 GPNMB EVL MMP2 CD109 CHD5 LGR6 PTPRD STARD8 RET ICAM5
Gender Male 98* 95 72 97 34 64 37 67** 61* 45 23
Female 90* 92 81 97 24 60 42 90** 84* 29 24
Age ,60 96 94 74 98 25 66 38 77 72 47 19
$60 94 94 77 96 37 58 43 71 67 31 29
Location Distal 95 93 74 98 21* 57 33 72 69 39 16*
proximal 95 95 78 95 43* 71 51 78 71 39 34*
Differentiation Poor 100 67 100 75* 0 67 50 75 50 0 0**
Moderate 97 97 77 98* 31 66 38 72 69 39 34**
Well 91 91 75 97* 34 50 38 78 69 38 6**
Stage 0,1 82* 94 65 94 24 82 71** 77 71 35 24
2 98* 93 78 100 27 49 24** 71 66 42 15
3,4 97* 94 75 95 35 61 43** 78 70 35 32
MSI High 100 91 83 100 33 61 38 92* 75 42 29
Non-MSI 94 95 72 96 30 62 40 70* 68 38 21
SYNE1 and REN were fully methylated and unmethylated, respectively for all samples tested.
*p,0.05 **p,0.01.
doi:10.1371/journal.pone.0007012.t005
Colon Cancer, Gene Methylation
PLoS ONE | www.plosone.org 5 September 2009 | Volume 4 | Issue 9 | e7012II and III disease, respectively. However, the difference was not
statistically significant. The loss of CHD5 expression was
consistent with CHD5 methylation in CRC. The cytoplasmic
expression of CHD5 was present in normal colon epithelial cells
(Fig. 2A) compared to the negative control without the primary
antibody (Fig. 2B), indicating the specificity of the antibody.
Discussion
Epigenetic analysis of tumor cells plays a major role in the
understanding of carcinogenic processes and targeted therapies
[7]. Sjoblom et al. have sequenced thousands of genes in 11
primary breast and colon tumors and concluded that every single
tumor has an average of 14 genetic alterations [11]. A subsequent
epigenetic and mutation study [10] led to the identification of
silenced promoters, 13 of which correspond to the CAN genes
analyzed in this study [11]. We decided to investigate the impact of
these 13 genes in CRC using two different sample populations.
Our choice of the 13 genes was based on the fact that they were
established from a high throughput technology and a compre-
hensive study involving both cell lines and clinical white colon
samples that were validated using DNA from normal and cancer
tissue [10,11,33]. Here, we analyzed the methylation profile of
these 13 genes in AA and Iranian CRC, the MSI status and the
expression by IHC of CHD5, a gene suspected to be involved in
early carcinogenic processes.
Most of the analyzed genes were highly methylated with
different levels of methylation from one gene to another and one
Figure2.Immunohistochemicalstaining ofCHD5 in human tissuemicroarray (A, B, C).(A)Positive CHD5stainingevidentin all of thenormal
glands in biopsy specimens from normal colon biopsies (B) in normal patients lack of brown color indicates absence of cytoplamic staining for CHD5 in
absence of primary antibody, (C)in CRC patients (.52%) of the cases showed absenceof cytoplasmic staining for CHD5 in the malignant epithelial cells.
doi:10.1371/journal.pone.0007012.g002
Figure 1. Graphical presentation of methylation frequencies
(%) of the CAN genes in the studied populations.
doi:10.1371/journal.pone.0007012.g001
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encoding protein, was methylated in all analyzed samples while
the RNF182 promoter, encoding a ring finger protein, was
methylated in none. No known function for the RNF182 gene is
available to date. SYNE1 protein was shown to be involved in the
process of cytokinesis [34] where this protein and KIF3B protein
facilitate the accumulation of membrane vesicles at the spindle
midbody.
The methylation profile of the analyzed genes was shown to be
independent of age (Table 5). While there is a general methylating
process that is age dependent and is not gene/disease specific, the
results obtained with the analyzed genes reflect the relevance of
these genes in the process of carcinogenic-dependent methylation.
These findings are strengthened by the fact that many of the
patients involved in this study, especially Iranians, are relatively
young (40 years).
At least four genes showed a level of methylation that depends on
the patient gender. A higher level of methylation in male patients was
found for APC2 and RET, while a higher level of methylation in
female patients was displayed for PTPRD and STARD8 genes
(Table 5). At least four genes (CD109, CHD5, LGR6, and ICAM5)
displayed a different level of methylation, depending on the tumor
location.Thesegenesshowedalowerlevelofmethylationinthedistal
colon. This finding is in agreement with the presence of a descending
methylation gradient from the proximal to the distal colon. A higher
level of methylation from well to poorly differentiated tumors was
observed only for the EVL gene promoter. Bournier et al. have
shown that the co-expression of the EVL protein along with alpha-II
spectrin reinforces the cell-to-cellinteraction [26]. The methylation of
the EVL gene in all poorly differentiated tumors and more than 75%
of well and moderately differentiated ones increases their invasive-
ness. This finding is strengthened by the fact that this gene
methylation increases also in advanced stage tumors where only
65% of stage-I tumors were methylated compared to 75% at stage
IV. An apparently stage-dependent methylation was observed for
LGR6, which encodes a Leucine-rich repeat-containing G-protein-
coupled receptor, and is thus involved in cell proliferation [13].
However, this decrease in methylation status from stage I to stage IV
(71% to 43%) cannot be explained in light of this gene function as a
proliferation promoter. APC2 stage-dependent methylation from
stage I to stage IV (82% to 97%) was also observed and this may be
consistent with the tumor suppressor activity of APC2 gene in CRC
and its link to the Wnt pathway.
The multivariate analysis for the effect of confounders (site,
differentiation and stage) is different among the two populations
(Table 3). To be confounders these variables need to be correlated
with methylation, too. As shown in table 5, ICAM5 is correlated
with differentiation and site while GPNMB and CHD5 are not
related to any of these variables. Based on these findings, site and
differentiation may have a confounder role for ICAM5. To be
consistent and inclusive in statistical analysis, we developed three
logistic regression models using forward selection with each gene
as dependent factor and site, population (Iranian vs. AA), stage,
and differentiation as independent factors. For all three models AA
remains the significant factor for methylation.
The methylation profile for all but one PTPRD gene was similar
in both MSI-H and non-MSI-H tumors, confirming an already-
established dissociation between the CpG island methylator
phenotype (CIMP) and the microsatellite instability phenotype in
colon cancer tumors. The PTPRD gene encodes a protein that is a
member of the protein tyrosine phosphatase family, signaling
molecules that regulate a variety of cellular processes including cell
growth, differentiation, mitotic cycle, and oncogenic transforma-
tion. Mori et al. (2004) have already shown that PTPR type O is
highly methylated in MSI-H tumors, strengthening our finding
[35].
A population-to-population comparison reveals a different
methylation profile between Iranians and AA for: GPNMB (89
vs. 100%), CHD5 (47 vs. 78%), LGR6 (31 vs. 49%), and ICAM5
(7.5 vs. 40%) with at least 3 statistically significant differences
(GPNMB, CHD5 and ICAM5). GPNMB, a type-I transmem-
brane glycoprotein, shows expression in the lowly metastatic
human melanoma cell lines but does not show expression in the
highly metastatic cell lines [36]. This gene’ product may be
involved in growth delay and reduction of metastatic potential.
Therefore, the higher methylation level of GPNMB in AA might
partly account for the high aggressiveness and fast progression of
colon tumors in AA. This finding is also reinforced by the fact that
another gene involved in metastasis, ICAM5, is highly methylated
in AA when compared to Iranians. ICAM5 encodes a type I
transmembrane glycoprotein that is a member of the intercellular
adhesion molecule (ICAM) family. High methylation level of
ICAM5 decreases the cell-to-cell adhesion in the corresponding
tumor cells, increasing their invasive potential. This finding is
consistent with the GPNMB results leading to cumulative effects
that increase the invasiveness and metastatic potential. Unlike
GPNMB and ICAM5, CHD-5 (chromodomain helicase DNA
binding protein 5) seems to be involved in early tumorigenic
processes at the chromatin remodeling level and controls events,
such as proliferation, apoptosis, and senescence, via the p19(Arf)/
p53 pathway [37]. The methylation level of this gene in AA (78%
vs. 47% in Iranians) might reflect the high level of incidence of
colon cancer in AA. Indeed, chromatin modification affects the
expression profiles of many genes at once and impacts the quick
progression of the tumor. Our recent publications have shown that
AA colon tumors display an aberrant global histone (H3, and H4)
acetylation and HDAC2 expression [38]. The hypermethylation of
those genes that showed similarities between the two populations
may be an early silencing marker for CRC initiation.
Based on the obtained results and known characteristics of AA
CRC, the CAN genes methylation results support the highly
methylated CHD5 and ICAM5 in the AA tumors, pointing to a
prominent role of CHD5 and ICAM5. There was a consistent
result between CHD5 methylation and lack of CHD5 protein
expression using IHC (Fig. 2). In addition, the expression and
functional analysis of these genes will be an important perspective
of this work that we are planning to address in future. Recently
CHD5 has been referred to as a tumor suppressor gene, which
supports our claim for epigenetic silencing [39] and its IHC
expression analysis. The methylation of CHD5 is a participating
factor in the higher incidence of CRC in AA along with other
markers (genetic and epigenetic). Differences in dietary, environ-
mental, and molecular genetic factors may also play a role
[2,40][41,42]. Racial disparities have been observed in lipoxygen-
ase polymorphisms [43], microsatellite instability [44], folate
metabolic gene polymorphisms [45], and vitamin D receptor
haplotypes [39,46].
The CAN genes could be referred to as CIMP markers since
there is no agreed upon standard CIMP list and different
laboratories have different CIMP genes list [12,47,48,49,50].
In conclusion, our study confirms the hypermethylation of
cancer candidate genes as biomarkers and a higher methylation
profile of GPNMB, ICAM5, and CHD5 genes in AA was
observed. Therefore, this may explain to certain extent the high
incidence and aggressiveness of CRC in AA. For a global view of
epigenetic processes in colon tumorigenesis in these groups of
patients, a thorough analysis of both populations’ tumors might
need to be done on established cell lines using agents targeting
Colon Cancer, Gene Methylation
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inhibitors followed by differential microarray expression studies.
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